Next Article in Journal
Achieving Dietary Sodium Recommendations and Atherosclerotic Cardiovascular Disease Prevention through Culinary Medicine Education
Next Article in Special Issue
Dietary Factors and Prostate Cancer Development, Progression, and Reduction
Previous Article in Journal
Verbal Memory Performance in Depressed Children and Adolescents: Associations with EPA but Not DHA and Depression Severity
Article

Therapeutic Potential of Gnetin C in Prostate Cancer: A Pre-Clinical Study

1
Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY 11201, USA
2
College of Veterinary Medicine, Long Island University, Brookville, NY 11548, USA
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Nutrients 2020, 12(12), 3631; https://doi.org/10.3390/nu12123631
Received: 3 November 2020 / Revised: 20 November 2020 / Accepted: 24 November 2020 / Published: 26 November 2020
(This article belongs to the Special Issue Nutrition Management for Prostate Cancer)
Natural stilbenes have gained significant attention in the scientific community owing to their potential anticancer effects against prostate cancer. We recently reported that Gnetin C, a resveratrol (Res) dimer, demonstrated more potent inhibition of metastasis-associated protein 1/v-ets avian erythroblastosis virus E26 oncogene homolog 2 (MTA1/ETS2) axis in prostate cancer cell lines than other stilbenes. In this study, we investigated in vivo antitumor effects of Gnetin C in two doses (50 and 25 mg/kg, i.p.) using PC3M-Luc subcutaneous xenografts and compared these to Res and pterostilbene (Pter). We found that while vehicle-treated mice revealed rapid tumor progression, compounds-treated mice showed noticeable delay in tumor growth. Gnetin C in 50 mg/kg dose demonstrated the most potent tumor inhibitory effects. Gnetin C in 25 mg/kg dose exhibited tumor inhibitory effects comparable with Pter in 50 mg/kg dose. Consistent with the effective antitumor effects, Gnetin C-treated tumors showed reduced mitotic activity and angiogenesis and a significant increase in apoptosis compared to all the other groups. The data suggest that Gnetin C is more potent in slowing tumor progression in prostate cancer xenografts than Res or Pter. Taken together, we demonstrated, for the first time, that Gnetin C is a lead compound among stilbenes for effectively blocking prostate cancer progression in vivo. View Full-Text
Keywords: Gnetin C; xenografts; therapy; MTA1; prostate cancer Gnetin C; xenografts; therapy; MTA1; prostate cancer
Show Figures

Figure 1

MDPI and ACS Style

Gadkari, K.; Kolhatkar, U.; Hemani, R.; Campanelli, G.; Cai, Q.; Kumar, A.; Levenson, A.S. Therapeutic Potential of Gnetin C in Prostate Cancer: A Pre-Clinical Study. Nutrients 2020, 12, 3631. https://doi.org/10.3390/nu12123631

AMA Style

Gadkari K, Kolhatkar U, Hemani R, Campanelli G, Cai Q, Kumar A, Levenson AS. Therapeutic Potential of Gnetin C in Prostate Cancer: A Pre-Clinical Study. Nutrients. 2020; 12(12):3631. https://doi.org/10.3390/nu12123631

Chicago/Turabian Style

Gadkari, Ketaki, Urvi Kolhatkar, Rutu Hemani, Gisella Campanelli, Qing Cai, Avinash Kumar, and Anait S. Levenson. 2020. "Therapeutic Potential of Gnetin C in Prostate Cancer: A Pre-Clinical Study" Nutrients 12, no. 12: 3631. https://doi.org/10.3390/nu12123631

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop